ABBV vs NERV
ABBV: Global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics targeting complex diseases. NERV: Minerva Neurosciences is a clinical-stage biopharmaceutical company developing novel treatments for central nervous system disorders, primarily focusing on schizophrenia.
Side-by-side fundamentals
| Metric | ABBV | NERV | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $256.91 | $4.20 | |
| Market cap as of 2026-07-31 | $453.9B | $196M | |
| P/E as of 2026-07-31 | 127.98 | 132.32 | ABBV lower |
| PEG as of 2026-07-31 | 5.72 | n/a | |
| Net margin as of 2026-07-31 | +5.8% | +4.7% | ABBV higher |
| Gross margin as of 2026-07-31 | +72.0% | n/a | |
| Operating margin as of 2026-07-31 | +24.4% | +4.5% | ABBV higher |
| ROE as of 2026-07-31 | +95.6% | -169.6% | ABBV higher |
| ROA as of 2026-07-31 | +2.7% | -662.8% | ABBV higher |
| Debt / equity as of 2026-07-31 | 49.22 | 0.00 | NERV lower |
| Revenue growth (YoY) as of 2026-07-31 | +9.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +1.8% | n/a | |
| Dividend yield as of 2026-07-31 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-31 | 0.27 | -0.01 | |
| 1-year return as of 2026-07-27 close | +35.0% | +97.4% | NERV higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.